Alembic Pharmaceuticals has reported results for the fourth quarter & year ended March 31, 2013.
The company has reported a surge of 114.92% in its net profit at Rs 43.65 crore in Q4FY13 as compared to net profit of Rs 20.31 crore in the same quarter previous year. Total income from operation of the company rose by 10.44% to Rs 378.08 crore as compared to Rs 342.34 crore in corresponding quarter last year.
For the full year, the company has reported a net profit of Rs 165.25 crore for the year ended March 31, 2013, a surge of 26.98% as compared to Rs 130.14 crore for the year ended March 31, 2012. Total income has increased to Rs 1520.34 crore in FY13 from Rs 1465.41 crore in FY12, up by 3.75%.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1672.80 |
| Dr. Reddys Lab | 1238.00 |
| Cipla | 1238.25 |
| Zydus Lifesciences | 942.95 |
| Lupin | 2333.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: